Genetic markers in newly diagnosed multiple myeloma

This study looks at “biomarkers,” or measurable signals in blood, in people with multiple myeloma who are being treated for the first time. It may help researchers understand the disease better and how it responds to treatment.

This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.

This study collects information and samples from people with multiple myeloma or related blood disorders to understand why the disease affects people differently. Researchers will use this information to develop better, personalized treatment approaches.

This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.

This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.

This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.